Oncomed Pharmaceuticals Inc (NASDAQ:OMED) – Stock analysts at SunTrust Banks issued their FY2022 earnings per share estimates for Oncomed Pharmaceuticals in a research note issued to investors on Thursday, Zacks Investment Research reports. SunTrust Banks analyst P. Lawson expects that the biopharmaceutical company will earn ($0.85) per share for the year. SunTrust Banks currently has a “Hold” rating and a $4.00 target price on the stock.
OMED has been the topic of several other reports. Zacks Investment Research cut shares of Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Jefferies Group reissued a “buy” rating and set a $5.00 price target on shares of Oncomed Pharmaceuticals in a research note on Thursday, September 28th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $6.00 price target on shares of Oncomed Pharmaceuticals in a research note on Tuesday, September 19th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $5.81.
Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) traded up $0.01 during trading on Monday, reaching $3.07. 371,085 shares of the company’s stock traded hands, compared to its average volume of 283,589. The company has a market capitalization of $116.22, a PE ratio of -1.62 and a beta of 2.80. Oncomed Pharmaceuticals has a 1 year low of $2.91 and a 1 year high of $10.89.
Oncomed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.41) by $0.13. The firm had revenue of $5.11 million for the quarter, compared to the consensus estimate of $6.25 million. Oncomed Pharmaceuticals’s quarterly revenue was down 13.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.77) earnings per share.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Disciplined Growth Investors Inc. MN grew its stake in shares of Oncomed Pharmaceuticals by 1.5% during the second quarter. Disciplined Growth Investors Inc. MN now owns 329,100 shares of the biopharmaceutical company’s stock valued at $1,096,000 after purchasing an additional 4,750 shares during the last quarter. Hodges Capital Management Inc. lifted its holdings in Oncomed Pharmaceuticals by 155.9% in the third quarter. Hodges Capital Management Inc. now owns 25,592 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 15,592 shares during the period. Citadel Advisors LLC lifted its holdings in Oncomed Pharmaceuticals by 289.8% in the second quarter. Citadel Advisors LLC now owns 45,997 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 34,197 shares during the period. Vanguard Group Inc. lifted its holdings in Oncomed Pharmaceuticals by 5.3% in the second quarter. Vanguard Group Inc. now owns 995,646 shares of the biopharmaceutical company’s stock valued at $3,315,000 after buying an additional 50,161 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Oncomed Pharmaceuticals by 1,426.7% in the second quarter. JPMorgan Chase & Co. now owns 83,345 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 77,886 shares during the period. 39.38% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Oncomed Pharmaceuticals Inc to Post FY2022 Earnings of ($0.85) Per Share, SunTrust Banks Forecasts (NASDAQ:OMED)” was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.truebluetribune.com/2018/01/16/suntrust-banks-comments-on-oncomed-pharmaceuticals-incs-fy2022-earnings-omed.html.
Oncomed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.